CIK 0001854270 · <br>Emerging growth company
Senti Biosciences Holdings, Inc.
Sign in to watch- Ticker
- SNTI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 862437900
- Phone
- (650) 239-2030
- Business address
- 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Senti Biosciences, Inc., Senti Biosciences, Inc.\, Dynamics Special Purpose Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-09 | Rajangam Kanya Pres. & Chief Med. & Dev. Off. | Grant or award · Series A Convertible Preferred Stock | +33 | $2,250.00 | $74K | 33 |
| 2024-12-09 | Rajangam Kanya Pres. & Chief Med. & Dev. Off. | Grant or award · Common Stock Warrant (right to buy) | +49,500 | 49,500 | ||
| 2024-07-10 | Farokhzad Omid Director | Grant or award · Stock Option (Right to Buy) | +62,500 | 62,500 | ||
| 2024-07-10 | Collins James J. Director | Grant or award · Stock Option (Right to Buy) | +62,500 | 62,500 | ||
| 2024-07-10 | COOPERSTONE BRENDA Director | Grant or award · Stock Option (Right to Buy) | +62,500 | 62,500 | ||
| 2024-07-10 | Mathers Edward T Director | Grant or award · Stock Option (Right to Buy) | +62,500 | 62,500 | ||
| 2024-02-01 | Rajangam Kanya Chief Medical & Devt. Officer | Grant or award | +101,000 | 101,000 | ||
| 2024-02-01 | Rajangam Kanya Chief Medical & Devt. Officer | Grant or award · Stock Option (Right to Buy) | +152,000 | 152,000 | ||
| 2024-02-01 | Lu Timothy K CEO and President | Grant or award | +306,000 | 865,496 | ||
| 2024-02-01 | Lu Timothy K CEO and President | Grant or award · Stock Option (Right to Buy) | +459,000 | 459,000 | ||
| 2024-02-01 | KNOBELMAN DEBORAH Chief Financial Officer | Grant or award | +101,000 | 131,000 | ||
| 2024-02-01 | KNOBELMAN DEBORAH Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +152,000 | 152,000 | ||
| 2023-06-16 | Berland Susan D Director | Grant or award · Stock Option (Right to Buy) | +62,500 | 62,500 | ||
| 2023-06-16 | Collins James J. Director | Grant or award · Stock Option (Right to Buy) | +62,500 | 62,500 | ||
| 2023-06-16 | COOPERSTONE BRENDA Director | Grant or award · Stock Option (Right to Buy) | +62,500 | 62,500 | ||
| 2023-06-16 | Farokhzad Omid Director | Grant or award · Stock Option (Right to Buy) | +62,500 | 62,500 | ||
| 2023-06-16 | Mathers Edward T Director | Grant or award · Stock Option (Right to Buy) | +62,500 | 62,500 | ||
| 2023-02-01 | Lee Philip J Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +195,000 | 195,000 | ||
| 2023-02-01 | KNOBELMAN DEBORAH Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +130,000 | 130,000 | ||
| 2023-02-01 | Rajangam Kanya Chief Medical & Devt. Officer | Grant or award · Stock Option (Right to Buy) | +130,000 | 130,000 |
Page 3 of 4 · 79 trades